About CardioBites
CardioBites are mobile-friendly, bite-sized videos providing focused education on important topics in the heart failure field. They can be watched anytime, anywhere on YouTube. No password. No barriers. Just easy access. Each CardioBites series is designed to educate physicians, scientists, nurses, nurse practitioners, pharmacists, and patients about the recent advances and emerging trends in heart failure.
Hyperkalemia is common among patients with cardiorenal disease and is associated with increased morbidity and mortality. Clinicians often reduce or discontinue renin-angiotensin-aldosterone system inhibitor (RAASi) therapy in response to hyperkalemia, despite this practice being associated with increased mortality, more heart failure hospitalizations, and faster kidney disease progression. This series explores the most recent clinical trial data and management of HF patients with hyperkalemia.
Impact of Hyperkalemia on HF GDMT Discontinuation and Down-Titration
Heart failure with reduced ejection fraction is a progressive condition associated with significant morbidity and mortality. Hyperkalemia is a clinically important and frequently encountered challenge in these patients. In this CardioBites, we explore why the 4 pillars of guideline-directed medical therapy are important and why discontinuing treatment when hyperkalemia occurs can negatively impact patient outcomes. Watch now!
Future Modules
- Potassium Binders and GDMT Optimization in Heart Failure (REALIZE-K)
- Management of Hyperkalemia in Heart Failure
- Risk and Consequences of Recurrent Hyperkalemia (GUARDIAN HK)
The full Hyperkalemia series can be accessed on YouTube.
Share Your Feedback & Stay Connected
This content was independently developed by HFSA; the program was funded by AstraZeneca.